X |
Filing Date |
Trade Date |
Ticker |
Company Name | Insider Name | Title |
Trade Type |
Price |
Qty |
Owned |
ΔOwn |
Value |
1d |
1w |
1m |
6m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D | 2026-01-22 | AXSM | Axsome Therapeutics, Inc. | Pizzie Nick | CFO | S - Sale+OE | $187.92 | -12,000 | 43,076 | -22% | -$2,255,040 | |||||
| D | 2026-01-21 | AXSM | Axsome Therapeutics, Inc. | Maizel Ari | Chief Commercial Officer | S - Sale+OE | $184.44 | -7,500 | 0 | -100% | -$1,383,300 | |||||
2026-01-22 | IONS | Ionis Pharmaceuticals Inc | Devers Shannon L. | EVP, Chief HR Ofc | S - Sale | $81.34 | -3,977 | 22,541 | -15% | -$323,490 | ||||||
| M | 2026-01-22 | SLGL | Sol-Gel Technologies Ltd. | Opaleye Management Inc. | 10% | P - Purchase | $56.36 | +3,324 | 459,844 | +1% | +$187,356 | |||||
2026-01-21 | RNA | Avidity Biosciences, Inc. | Hughes Steven George | Chief Medical Officer | S - Sale | $72.45 | -4,895 | 31,599 | -13% | -$354,643 | ||||||
2026-01-21 | RNA | Avidity Biosciences, Inc. | Boyce Sarah | Pres, CEO | S - Sale | $72.45 | -14,387 | 269,007 | -5% | -$1,042,338 | ||||||
2026-01-21 | RNA | Avidity Biosciences, Inc. | Flanagan W. Michael | Chief Scientific Officer | S - Sale | $72.45 | -6,534 | 85,093 | -7% | -$473,388 | ||||||
2026-01-21 | RNA | Avidity Biosciences, Inc. | Maclean Michael F | CFO | S - Sale | $72.45 | -4,542 | 59,290 | -7% | -$329,068 | ||||||
2026-01-21 | RNA | Avidity Biosciences, Inc. | Levin Arthur A | Dir | S - Sale | $72.45 | -1,758 | 170,434 | -1% | -$127,367 | ||||||
2026-01-21 | RNA | Avidity Biosciences, Inc. | McCarthy Teresa | CHRO | S - Sale | $72.45 | -2,929 | 113,938 | -3% | -$212,206 | ||||||
| M | 2026-01-22 | CLNN | Clene Inc. | Ugwumba Chidozie | 10% | S - Sale | $5.30 | -18,221 | 599,603 | -3% | -$96,658 | |||||
| D | 2026-01-22 | MIRM | Mirum Pharmaceuticals, Inc. | Howe Jolanda | SVP, GLOBAL CONTROLLER | S - Sale+OE | $93.33 | -926 | 3,042 | -23% | -$86,419 | |||||
| D | 2026-01-22 | MIRM | Mirum Pharmaceuticals, Inc. | Quan Joanne | CHIEF MEDICAL OFFICER | S - Sale+OE | $93.33 | -1,822 | 12,817 | -12% | -$170,039 | |||||
| D | 2026-01-22 | MIRM | Mirum Pharmaceuticals, Inc. | Bjerkholt Eric | CFO | S - Sale+OE | $93.33 | -1,421 | 42,127 | -3% | -$132,615 | |||||
| D | 2026-01-22 | MIRM | Mirum Pharmaceuticals, Inc. | Radovich Peter | Pres, COO | S - Sale+OE | $93.33 | -2,382 | 20,679 | -10% | -$222,301 | |||||
| D | 2026-01-22 | MIRM | Mirum Pharmaceuticals, Inc. | Peetz Christopher | CEO | S - Sale+OE | $93.33 | -7,098 | 351,233 | -2% | -$662,422 | |||||
2026-01-20 | RPRX | Royalty Pharma Plc | Coyne Terrance P. | EVP, CFO | S - Sale | $39.35 | -69,582 | 481,396 | -13% | -$2,737,940 | ||||||
| DM | 2026-01-21 | NUVL | Nuvalent, Inc. | Miller Deborah Ann | GC | S - Sale+OE | $110.15 | -15,000 | 59,634 | -20% | -$1,652,176 | |||||
2026-01-22 | APLS | Apellis Pharmaceuticals, Inc. | Baumal Caroline | Chief Medical Officer | S - Sale | $21.77 | -2,797 | 86,527 | -3% | -$60,878 | ||||||
2026-01-22 | APLS | Apellis Pharmaceuticals, Inc. | Chopas James George | VP, Chief Accounting Officer | S - Sale | $21.77 | -2,064 | 49,805 | -4% | -$44,924 | ||||||
2026-01-22 | APLS | Apellis Pharmaceuticals, Inc. | Delong Mark Jeffrey | Chief Business, Strat Officer | S - Sale | $21.77 | -3,371 | 78,353 | -4% | -$73,371 | ||||||
2026-01-22 | APLS | Apellis Pharmaceuticals, Inc. | Deschatelets Pascal | Chief Scientific Officer | S - Sale | $21.77 | -5,928 | 1,151,382 | -1% | -$129,025 | ||||||
2026-01-22 | APLS | Apellis Pharmaceuticals, Inc. | Francois Cedric | CEO | S - Sale | $21.77 | -27,192 | 1,600,467 | -2% | -$591,845 | ||||||
2026-01-22 | APLS | Apellis Pharmaceuticals, Inc. | Nicholson Nur | Chief Technical Officer | S - Sale | $21.77 | -7,725 | 71,118 | -10% | -$168,138 | ||||||
2026-01-22 | APLS | Apellis Pharmaceuticals, Inc. | Sullivan Timothy Eugene | CFO | S - Sale | $21.77 | -10,287 | 154,297 | -6% | -$223,901 | ||||||
2026-01-22 | APLS | Apellis Pharmaceuticals, Inc. | Watson David O. | GC | S - Sale | $21.77 | -7,832 | 148,667 | -5% | -$170,467 | ||||||
| D | 2026-01-21 | PVLA | Palvella Therapeutics, Inc. | Goin Kathleen | COO | S - Sale+OE | $97.63 | -4,302 | 0 | -100% | -$419,983 | |||||
| D | 2026-01-21 | EWTX | Edgewise Therapeutics, Inc. | Edris Badreddin | Dir | S - Sale+OE | $29.44 | -115,471 | 19,820 | -85% | -$3,399,466 | |||||
| D | 2026-01-22 | SER | Serina Therapeutics, Inc. | Moreadith Randall | Chief Scientific Officer | S - Sale+OE | $2.95 | -2,500 | 0 | -100% | -$7,375 | |||||
2026-01-20 | PLRX | Pliant Therapeutics, Inc. | Cummings Keith Lamont | CFO | S - Sale | $1.28 | -24,002 | 297,214 | -7% | -$30,723 | ||||||
2026-01-20 | PLRX | Pliant Therapeutics, Inc. | Cheung Lily | Chief Human Resource Officer | S - Sale | $1.28 | -7,534 | 44,847 | -14% | -$9,644 | ||||||
2026-01-20 | PLRX | Pliant Therapeutics, Inc. | Coulie Bernard | Pres, CEO | S - Sale | $1.28 | -89,375 | 914,918 | -9% | -$114,400 | ||||||
2026-01-20 | PLRX | Pliant Therapeutics, Inc. | Kuo Minnie | COO | S - Sale | $1.28 | -6,917 | 37,806 | -15% | -$8,854 | ||||||
2026-01-21 | CRMD | Cormedix Inc. | Dillione Janet | Dir | S - Sale | $6.88 | -10,000 | 38,473 | -21% | -$68,800 | ||||||
2026-01-22 | ABEO | Abeona Therapeutics Inc. | Vazzano Joseph Walter | CFO | S - Sale | $5.33 | -18,666 | 568,560 | -3% | -$99,507 | ||||||
2026-01-22 | ABEO | Abeona Therapeutics Inc. | Seshadri Vishwas | CEO | S - Sale | $5.33 | -69,832 | 1,460,408 | -5% | -$372,267 | ||||||
2026-01-22 | ABEO | Abeona Therapeutics Inc. | O'Malley Brendan M. | SVP, GC | S - Sale | $5.33 | -13,578 | 451,134 | -3% | -$72,383 | ||||||
| D | 2026-01-22 | COGT | Cogent Biosciences, Inc. | Fairmount Funds Management LLC | Dir | S - Sale+OE | $36.40 | -3,500,000 | 5,503,418 | -39% | -$127,400,000 | |||||
| M | 2026-01-21 | PAHC | Phibro Animal Health Corp | Bendheim Jack | Pres, CEO, 10% | S - Sale | $41.82 | -27,845 | 33,520 | -45% | -$1,164,547 | |||||
2026-01-20 | NKTR | Nektar Therapeutics | Zalevsky Jonathan | Chief R, D Officer | S - Sale | $35.67 | -3,867 | 21,354 | -15% | -$137,936 | ||||||
| D | 2026-01-20 | FOLD | Amicus Therapeutics, Inc. | Campbell Bradley L | Pres, CEO | S - Sale+OE | $14.31 | -75,000 | 1,021,180 | -7% | -$1,073,183 | |||||
2026-01-20 | RAPP | Rapport Therapeutics, Inc. | Ceesay Abraham | CEO | S - Sale | $26.12 | -10,916 | 669,621 | -2% | -$285,071 | ||||||
2026-01-20 | ELVN | Enliven Therapeutics, Inc. | Lyssikatos Joseph P | CHIEF SCIENTIFIC OFFICER | S - Sale | $26.75 | -20,000 | 745,188 | -3% | -$535,099 | ||||||
2026-01-20 | ELVN | Enliven Therapeutics, Inc. | Heyman Richard A. | Dir | S - Sale | $26.75 | -1,230 | 173,095 | -1% | -$32,902 | ||||||
| DM | 2026-01-20 | NAMS | Newamsterdam Pharma Co N.V. | Somaiya Mayur Ian | CFO | S - Sale+OE | $32.61 | -100,000 | 58,382 | -63% | -$3,260,618 | |||||
| D | 2026-01-20 | INSM | Insmed Inc | Lewis William | Chair, CEO | S - Sale+OE | $158.93 | -10,699 | 591,315 | -2% | -$1,700,411 | |||||
2026-01-21 | KPTI | Karyopharm Therapeutics Inc. | Abate Kristin | Chief Accounting Officer | S - Sale | $5.96 | -265 | 22,580 | -1% | -$1,579 | ||||||
| AD | 2025-12-12 | OGEN | Oragenics Inc | Telling Fred | Dir | S - Sale+OE | $0.94 | -210 | 948 | -18% | -$198 | |||||
2026-01-21 | RNXT | Renovorx, Inc. | Agah Ramtin | Chief Medical Officer | P - Purchase | $1.00 | +10,000 | 798,460 | +1% | +$9,975 | ||||||
2026-01-20 | OLMA | Olema Pharmaceuticals, Inc. | Harmon Cyrus | Dir | S - Sale | $26.88 | -10,000 | 844,798 | -1% | -$268,800 | ||||||
| DM | 2026-01-20 | SER | Serina Therapeutics, Inc. | Moreadith Randall | Chief Scientific Officer | S - Sale+OE | $3.04 | -4,000 | 0 | -100% | -$12,140 | |||||
| D | 2026-01-20 | IRON | Disc Medicine, Inc. | Khara Rahul | GC | S - Sale+OE | $69.74 | -1,000 | 37,793 | -3% | -$69,740 | |||||
| M | 2026-01-16 | CLNN | Clene Inc. | Ugwumba Chidozie | 10% | S - Sale | $4.97 | -32,474 | 617,824 | -5% | -$161,520 | |||||
2026-01-20 | PTGX | Protagonist Therapeutics, Inc | Molina Arturo Md | Chief Medical Officer | S - Sale | $82.48 | -9,514 | 97,266 | -9% | -$784,715 | ||||||
2026-01-20 | ESPR | Esperion Therapeutics, Inc. | Looker Benjamin | GC | S - Sale | $2.88 | -1,689 | 384,216 | 0% | -$4,868 | ||||||
2026-01-20 | PTGX | Protagonist Therapeutics, Inc | Patel Dinesh V Ph D | Pres, CEO | S - Sale | $82.48 | -34,438 | 580,505 | -6% | -$2,840,446 | ||||||
2026-01-20 | PTGX | Protagonist Therapeutics, Inc | Ali Asif | CFO | S - Sale | $82.48 | -8,588 | 78,077 | -10% | -$708,338 | ||||||
2026-01-21 | ABEO | Abeona Therapeutics Inc. | Alvino Mark | Dir | S - Sale | $5.23 | -13,500 | 48,752 | -22% | -$70,574 | ||||||
2026-01-20 | APLS | Apellis Pharmaceuticals, Inc. | Baumal Caroline | Chief Medical Officer | S - Sale | $19.79 | -1,882 | 89,324 | -2% | -$37,250 | ||||||
2026-01-20 | APLS | Apellis Pharmaceuticals, Inc. | Chopas James George | VP, Chief Accounting Officer | S - Sale | $19.79 | -726 | 51,869 | -1% | -$14,370 | ||||||
2026-01-20 | APLS | Apellis Pharmaceuticals, Inc. | Delong Mark Jeffrey | Chief Business, Strat Officer | S - Sale | $19.79 | -1,334 | 81,724 | -2% | -$26,404 | ||||||
2026-01-20 | APLS | Apellis Pharmaceuticals, Inc. | Deschatelets Pascal | Chief Scientific Officer | S - Sale | $19.79 | -909 | 1,157,310 | 0% | -$17,992 | ||||||
2026-01-20 | APLS | Apellis Pharmaceuticals, Inc. | Francois Cedric | CEO | S - Sale | $19.79 | -8,182 | 1,627,659 | -1% | -$161,946 | ||||||
2026-01-20 | APLS | Apellis Pharmaceuticals, Inc. | Nicholson Nur | Chief Technical Officer | S - Sale | $19.79 | -2,203 | 78,843 | -3% | -$43,604 | ||||||
2026-01-20 | APLS | Apellis Pharmaceuticals, Inc. | Sullivan Timothy Eugene | CFO | S - Sale | $19.79 | -2,892 | 164,584 | -2% | -$57,241 | ||||||
2026-01-20 | APLS | Apellis Pharmaceuticals, Inc. | Watson David O. | GC | S - Sale | $19.79 | -2,475 | 156,499 | -2% | -$48,987 | ||||||
| D | 2026-01-20 | TVTX | Travere Therapeutics, Inc. | Reed Elizabeth E | GC, GC | S - Sale+OE | $27.34 | -10,000 | 90,270 | -10% | -$273,420 | |||||
| D | 2026-01-20 | MIRM | Mirum Pharmaceuticals, Inc. | Quan Joanne | CHIEF MEDICAL OFFICER | S - Sale+OE | $90.27 | -6,911 | 11,305 | -38% | -$623,853 | |||||
2026-01-21 | XCUR | Exicure, Inc. | Exicure Hitron Inc. | 10% | S - Sale | $4.50 | -258,367 | 1,598,947 | -14% | -$1,162,652 | ||||||
2026-01-16 | IMRX | Immuneering Corp | Brakewood Harold Eugene | Chief Business Officer | P - Purchase | $4.76 | +5,250 | 11,050 | +91% | +$24,990 | ||||||
| DM | 2026-01-15 | AMLX | Amylyx Pharmaceuticals, Inc. | Cohen Joshua B | Co-CEO | S - Sale+OE | $13.59 | -138,167 | 3,379,465 | -4% | -$1,878,094 | |||||
| DM | 2026-01-15 | AMLX | Amylyx Pharmaceuticals, Inc. | Klee Justin B. | Co-CEO | S - Sale+OE | $13.59 | -138,188 | 3,379,398 | -4% | -$1,877,570 | |||||
2026-01-15 | HRMY | Harmony Biosciences Holdings, Inc. | Kapadia Sandip | CFO | S - Sale | $35.92 | -20,961 | 0 | -100% | -$752,833 | ||||||
| D | 2026-01-20 | MLYS | Mineralys Therapeutics, Inc. | Rodman David Malcom | Chief Medical Officer | S - Sale+OE | $32.10 | -416 | 50,437 | -1% | -$13,354 | |||||
| D | 2026-01-16 | IONS | Ionis Pharmaceuticals Inc | Swayze Eric | EVP Research | S - Sale+OE | $75.34 | -9,933 | 42,253 | -19% | -$748,383 | |||||
| D | 2026-01-16 | IONS | Ionis Pharmaceuticals Inc | Schneider Eugene | EVP, Chf Clinical Develop Ofcr | S - Sale+OE | $75.59 | -9,302 | 63,890 | -13% | -$703,138 | |||||
| D | 2026-01-16 | IONS | Ionis Pharmaceuticals Inc | O'Neil Patrick R. | EVP CLO, GC | S - Sale+OE | $75.84 | -9,191 | 66,171 | -12% | -$697,045 | |||||
| D | 2026-01-16 | IONS | Ionis Pharmaceuticals Inc | Monia Brett P | CEO | S - Sale+OE | $74.82 | -44,034 | 224,683 | -16% | -$3,294,624 | |||||
| D | 2026-01-16 | IONS | Ionis Pharmaceuticals Inc | Kordasiewicz Holly B. | EVP, Chief Development Officer | S - Sale+OE | $75.66 | -4,141 | 14,718 | -22% | -$313,308 | |||||
| D | 2026-01-16 | IONS | Ionis Pharmaceuticals Inc | Jenne Kyle | EVP, Chf GL Pdt Str Ofcr | S - Sale+OE | $75.96 | -1,823 | 16,389 | -10% | -$138,475 | |||||
| D | 2026-01-16 | IONS | Ionis Pharmaceuticals Inc | Devers Shannon L. | EVP, Chief HR Ofc | S - Sale+OE | $75.95 | -8,353 | 26,518 | -24% | -$634,410 | |||||
| D | 2026-01-16 | IONS | Ionis Pharmaceuticals Inc | Birchler Brian | EVP, Corp, Development Ops | S - Sale+OE | $75.11 | -8,480 | 60,435 | -12% | -$636,933 | |||||
| D | 2026-01-16 | IONS | Ionis Pharmaceuticals Inc | Bennett C Frank | EVP, Chief Scientific Officer | S - Sale+OE | $75.15 | -8,977 | 94,757 | -9% | -$674,622 | |||||
| D | 2026-01-16 | IONS | Ionis Pharmaceuticals Inc | Baroldi Joseph | EVP, Chief Business Officer | S - Sale+OE | $75.75 | -8,056 | 45,203 | -15% | -$610,276 | |||||
| D | 2026-01-20 | NRIX | Nurix Therapeutics, Inc. | Ring Christine | GC | S - Sale+OE | $18.42 | -3,760 | 50,897 | -7% | -$69,273 | |||||
2026-01-16 | ORIC | Oric Pharmaceuticals, Inc. | Heyman Richard A. | Dir | S - Sale | $12.00 | -6,700 | 254,872 | -3% | -$80,431 | ||||||
2026-01-20 | MDGL | Madrigal Pharmaceuticals, Inc. | Kelley Shannon T | GC | S - Sale | $497.36 | -692 | 8,481 | -8% | -$344,173 | ||||||
2026-01-20 | MDGL | Madrigal Pharmaceuticals, Inc. | Taub Rebecca | Dir | S - Sale | $490.77 | -2,238 | 1,108,891 | 0% | -$1,098,343 | ||||||
2026-01-15 | NKTX | Nkarta, Inc. | Hastings Paul J | CEO | S - Sale | $2.07 | -26,046 | 390,023 | -6% | -$53,915 | ||||||
2026-01-15 | NKTX | Nkarta, Inc. | Mahmood Nadir | Pres | S - Sale | $2.07 | -5,649 | 167,727 | -3% | -$11,693 | ||||||
2026-01-16 | RPRX | Royalty Pharma Plc | Urist Marshall | EVP, Research, Investments | S - Sale | $39.52 | -20,000 | 66,418 | -23% | -$790,346 | ||||||
2026-01-15 | BCAX | Bicara Therapeutics Inc. | Cohlhepp Ryan | Pres, COO | S - Sale | $18.02 | -149 | 213,992 | 0% | -$2,685 | ||||||
| D | 2026-01-15 | DVAX | Dynavax Technologies Corp | Novack David F | Pres, COO | S - Sale+OE | $15.64 | -114,000 | 63,344 | -64% | -$1,782,960 | |||||
2026-01-16 | UTHR | United Therapeutics Corp | Malcolm Jan | Dir | S - Sale | $460.98 | -50 | 320 | -14% | -$23,049 | ||||||
2026-01-16 | ONCY | Oncolytics Biotech Inc | Seizinger Bernd R. | Dir | P - Purchase | $1.04 | +100,000 | 466,991 | +27% | +$103,770 | ||||||
2026-01-12 | TYRA | Tyra Biosciences, Inc. | Bensen Daniel | Chief Discovery Officer | S - Sale | $28.52 | -8,000 | 154,981 | -5% | -$228,186 | ||||||
2026-01-16 | HOWL | Werewolf Therapeutics, Inc. | Evnin Luke | Dir | S - Sale | $0.54 | -38,782 | 2,159,860 | -2% | -$20,942 | ||||||
2026-01-16 | XCUR | Exicure, Inc. | Exicure Hitron Inc. | 10% | S - Sale | $4.50 | -734,747 | 1,857,314 | -28% | -$3,306,362 | ||||||
| A | 2025-10-17 | MYNZ | Mainz Biomed N.V. | Donahue Kevin Michael | 10% | P - Purchase | $1.51 | +685,000 | 685,000 | New | +$1,034,350 | |||||
2026-01-15 | IMRX | Immuneering Corp | Schall Thomas J. | Dir | P - Purchase | $4.67 | +21,645 | 74,530 | +41% | +$101,041 |
| A | Amended filing |
| D | Derivative transaction in filing (usually option exercise) |
| E | Error detected in filing |
| M | Multiple transactions in filing; earliest reported transaction date and weighted average transaction price |
| S - Sale | Sale of securities on an exchange or to another person |
| S - Sale+OE | Sale of securities on an exchange or to another person (after option exercise) |
| F - Tax | Payment of exercise price or tax liability using portion of securities received from the company |
| P - Purchase | Purchase of securities on an exchange or from another person |